Research6 Dec 2020 18:06
Great summary of the enormity of the opportunity at stake here from the CTEA telegram group...
CTEA recently formed a JV with Blackhive Africa Medical's UK and SA subsidiaries - BHA Medical - through Onside Now, which changed name to Synovate Global (www.synovateglobal.com) which is building out its website and service.
Synovate provides a holistic COVID and other infectious disease ‘Test, Monitor, Manage’ service powered by a globally scalable Blockchain powered dynamic intelligence dashboard linked to various App solutions.
Dynamic intelligence dashboards were launched along with the COV-ID App upgrade as per 25 August RNS. The dashboards allow central co-ordinators to monitor and manage their population health include COVID status. Signs of rollout of similar technologies across NHS and GP hubs for testing and vaccines are starting to emerge in the press.
CTEA's solution is GDPR compliant, super fast and immutable. Like BHA, the business is highly scalable.
BHA has exclusivity to supply the Antai Triple Antibody test to the UK and more recently the sub-saharan Africa region the latter accounting for 80% of Africa or over 1.1bn people. Over 350k Antai tests had been supplied to UK businesses by October, and these businesses were interested in piloting the holistic service brought in by CTEA.
BHA also supplies the Healgen Antigen LFT test, which passed PHE's Porton Down lab tests in October and then subsequently ranked 1 by the UK Gov's REACT 2 group out of 11 evaluated.
The company is targeting government and large corporate opportunities. For example, mass testing programmes and B2B contracts with potential to expand into the 15bn dose global vaccination programme, and for African disease accounting for 10x as many tests required than COVID in the SADC region covering c.450m people.
CTEA in November signed an MoU with Afrik-ID, which seeks to access the service of Synovate for this purpose in SADC.
Guy Meyers, CTEA CEO, in October's Proactive interview stated ‘we are at a cliff edge in terms of growth'.
Exciting times ahead and from £6m market cap and very little herd interest, the shares are primed to multiply if Synovate or CTEA singularly secures large contracts such as verifying the qualifications or legal status of workers in the construction industry post-Brexit, which was one the original target applications of Onsite ID pre-COVID.
A well known use case for Blockchain is in the field of Supply Chain Management. The global vaccination programme may yet see further mass opportunity open to Synovate or CTEA.
According to Teeka Tiwani, arguably the US's most successful investor, Blockchain represents a $1k to $1m opportunity - Amazon, Apple and Microsoft type gains. Bigger than 5G and the biggest opportunity since the internet. He calls now the 'adoption phase'.
Sign In
Follow the stocks
